MEOBF
Price
$1.54
Change
+$0.03 (+1.99%)
Updated
Aug 14 closing price
Capitalization
2.1B
11 days until earnings call
MESO
Price
$16.25
Change
+$0.39 (+2.46%)
Updated
Aug 15 closing price
Capitalization
2.1B
11 days until earnings call
Interact to see
Advertisement

MEOBF vs MESO

Header iconMEOBF vs MESO Comparison
Open Charts MEOBF vs MESOBanner chart's image
Mesoblast
Price$1.54
Change+$0.03 (+1.99%)
Volume$1.95K
Capitalization2.1B
Mesoblast
Price$16.25
Change+$0.39 (+2.46%)
Volume$226.25K
Capitalization2.1B
MEOBF vs MESO Comparison Chart in %
Loading...
MEOBF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MESO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MEOBF vs. MESO commentary
Aug 16, 2025

To understand the difference between Mesoblast Ltd (MEOBF) vs. Mesoblast Ltd - ADR (MESO) it is enough to know the definitions of ADR

ADR - American depositary receipt (ADR) is a certificate issued by a U.S. depositary bank representing a specified number of shares (often 1 share) of a foreign company's stock. ADRs are denominated in U.S. dollars and trade on U.S. stock markets and OTC depending on the ADRs classification.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 16, 2025
Stock price -- (MEOBF: $1.54 vs. MESO: $16.25)
Brand notoriety: MEOBF and MESO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MEOBF: 246% vs. MESO: 93%
Market capitalization -- MEOBF: $2.1B vs. MESO: $2.1B
MEOBF [@Biotechnology] is valued at $2.1B. MESO’s [@Biotechnology] market capitalization is $2.1B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.71B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MEOBF’s FA Score shows that 0 FA rating(s) are green whileMESO’s FA Score has 0 green FA rating(s).

  • MEOBF’s FA Score: 0 green, 5 red.
  • MESO’s FA Score: 0 green, 5 red.
According to our system of comparison, MEOBF is a better buy in the long-term than MESO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MEOBF’s TA Score shows that 3 TA indicator(s) are bullish while MESO’s TA Score has 5 bullish TA indicator(s).

  • MEOBF’s TA Score: 3 bullish, 2 bearish.
  • MESO’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both MEOBF and MESO are a good buy in the short-term.

Price Growth

MEOBF (@Biotechnology) experienced а +1.99% price change this week, while MESO (@Biotechnology) price change was +8.12% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.90%. For the same industry, the average monthly price growth was +26.70%, and the average quarterly price growth was +20.91%.

Reported Earning Dates

MEOBF is expected to report earnings on Aug 27, 2025.

MESO is expected to report earnings on Aug 27, 2025.

Industries' Descriptions

@Biotechnology (+9.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MEOBF($2.1B) and MESO($2.1B) have the same market capitalization . MESO YTD gains are higher at: -17.929 vs. MEOBF (-30.000). MEOBF (-77.78M) and MESO (-77.78M) have comparable annual earnings (EBITDA) . MEOBF (37.7M) and MESO (37.7M) have equal amount of cash in the bank . MEOBF (126M) and MESO (126M) have identical debt. MEOBF (5.67M) and MESO (5.67M) have equivalent revenues.
MEOBFMESOMEOBF / MESO
Capitalization2.1B2.1B100%
EBITDA-77.78M-77.78M100%
Gain YTD-30.000-17.929167%
P/E RatioN/AN/A-
Revenue5.67M5.67M100%
Total Cash37.7M37.7M100%
Total Debt126M126M100%
FUNDAMENTALS RATINGS
MEOBF vs MESO: Fundamental Ratings
MEOBF
MESO
OUTLOOK RATING
1..100
4325
VALUATION
overvalued / fair valued / undervalued
1..100
87
Overvalued
88
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9595
PRICE GROWTH RATING
1..100
3737
P/E GROWTH RATING
1..100
5597
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MEOBF's Valuation (87) in the null industry is in the same range as MESO (88) in the Biotechnology industry. This means that MEOBF’s stock grew similarly to MESO’s over the last 12 months.

MEOBF's Profit vs Risk Rating (100) in the null industry is in the same range as MESO (100) in the Biotechnology industry. This means that MEOBF’s stock grew similarly to MESO’s over the last 12 months.

MEOBF's SMR Rating (95) in the null industry is in the same range as MESO (95) in the Biotechnology industry. This means that MEOBF’s stock grew similarly to MESO’s over the last 12 months.

MEOBF's Price Growth Rating (37) in the null industry is in the same range as MESO (37) in the Biotechnology industry. This means that MEOBF’s stock grew similarly to MESO’s over the last 12 months.

MEOBF's P/E Growth Rating (55) in the null industry is somewhat better than the same rating for MESO (97) in the Biotechnology industry. This means that MEOBF’s stock grew somewhat faster than MESO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MEOBFMESO
RSI
ODDS (%)
Bearish Trend 2 days ago
55%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
64%
Bearish Trend 2 days ago
84%
Momentum
ODDS (%)
N/A
Bullish Trend 2 days ago
77%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
52%
Bullish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
50%
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
N/A
Bullish Trend 2 days ago
81%
Declines
ODDS (%)
N/A
Bearish Trend 6 days ago
84%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
88%
Aroon
ODDS (%)
Bullish Trend 2 days ago
57%
Bullish Trend 2 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
MEOBF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MESO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FGIGX44.250.22
+0.50%
American Funds Intl Gr and Inc529-F-3
IAVGX21.19N/A
N/A
Voya Growth and Income Port A
SEECX37.98N/A
N/A
Steward Values Enhanced Lg Cap I
FHJMX45.19N/A
N/A
Fidelity Advisor Europe I
MICHX11.07N/A
N/A
Matthews China Small Companies Instl

MEOBF and

Correlation & Price change

A.I.dvisor indicates that over the last year, MEOBF has been loosely correlated with SPHDF. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if MEOBF jumps, then SPHDF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MEOBF
1D Price
Change %
MEOBF100%
N/A
SPHDF - MEOBF
50%
Loosely correlated
N/A
AVTX - MEOBF
46%
Loosely correlated
+0.78%
COGT - MEOBF
39%
Loosely correlated
+1.54%
MESO - MEOBF
26%
Poorly correlated
+2.46%
KROS - MEOBF
26%
Poorly correlated
+0.42%
More

MESO and

Correlation & Price change

A.I.dvisor indicates that over the last year, MESO has been loosely correlated with QTTB. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if MESO jumps, then QTTB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MESO
1D Price
Change %
MESO100%
+2.46%
QTTB - MESO
51%
Loosely correlated
+4.79%
TNGX - MESO
33%
Poorly correlated
-2.17%
AVTX - MESO
32%
Poorly correlated
+0.78%
ZURA - MESO
32%
Poorly correlated
-3.49%
RAPT - MESO
30%
Poorly correlated
+4.36%
More